Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
about
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine modelRifabutin for treating pulmonary tuberculosisWeekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Antituberculosis therapy for 2012 and beyondBactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans diseaseRandomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in VietnamThe Role of Adherence and Retreatment in De Novo Emergence of MDR-TBA multi-scale approach to designing therapeutics for tuberculosisTuberculosis therapy for 2016 and beyond.Insights into the pharmacokinetic properties of antitubercular drugs.Advances in the diagnosis and treatment of tuberculosis.The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity.Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetesDaily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsPharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.Treatment Options for HIV-Associated Tuberculosis.How antibiotics kill bacteria: from targets to networksNew drugs to treat multidrug-resistant tuberculosis: the case for bedaquilineEffects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.AtriplaR/anti-TB combination in TB/HIV patients. Drug in focusEffects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Pharmacological issues in the treatment of tuberculosis.Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteersImpact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapyPharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.The use of anti-tuberculosis therapy for latent TB infectionInitiating antiretrovirals during tuberculosis treatment: a drug safety review.Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.Current development and future prospects in chemotherapy of tuberculosisThe ethics of a clinical trial when the protocol clashes with international guidelines.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsPotent twice-weekly rifapentine-containing regimens in murine tuberculosis.
P2860
Q21144660-85A3A035-BCAA-48B9-B74B-3607EDEA43FEQ24242892-0FBD764A-46AF-4B36-A6E7-E31197929F42Q24650581-90B2D5E9-A2B3-4B9D-958F-A59CB728E1EBQ25255438-00D95EC2-AEBB-4CBC-B766-A2881F5BC5BEQ26829101-322A895C-E7BA-4905-BD93-1F1763AF152AQ28487137-3E9B24C0-EA58-4E21-AF62-A0B7E90A9D24Q28538952-E3ED7616-D678-4F0B-B02D-C1A6B72D9199Q28550707-6C1E86F7-9354-438E-AB5C-13BD77453B23Q28647309-D93A3474-279C-4E1F-A5BF-B76592D7B9F3Q30248788-F9A7CA60-6AF6-461A-98E6-F8DCEBD4C09FQ30251497-17DA5F6F-4890-480F-B037-864B3D08A921Q30353049-7B2D228F-37BA-410E-A951-4FC9C93E7A5CQ30381972-671D1AA8-B015-42B6-9764-41FDD3BE7F23Q30478126-84305B99-0658-4258-92ED-10072062C00EQ33282527-7A8E2AA1-E26F-40F5-808B-2D4432291F39Q33521011-A5750A63-E5AA-47AD-BBE5-D44A3A2895EAQ33735589-9DECEE62-406E-4FDF-A3EB-6E5839EA041DQ33763177-34AF6097-644C-44BC-B714-5DE98B3D3664Q33805141-0636C8BA-D971-436D-8A35-5F7FA7E31A97Q33813097-E6027046-5F78-4FF1-B589-F5EFDE609B9AQ33958766-B1DB28FA-0497-4DA0-AB8E-C3ADD5C99E03Q34005593-5C3C7B04-C472-43C0-8FD5-C9810AC10FB3Q34045240-0DA63EF9-632C-473D-9AC5-F91A2992F5A5Q34083071-AB09FAE4-3F16-4E78-BF16-80B10637A7C1Q34150929-0A71AD68-A93F-4C29-8735-CEE9C358E148Q34497277-1C23FCD4-78FF-4D2B-AFA6-332805D8FC67Q34510679-DA3569A2-220F-46E7-8CB2-F699089A3FEBQ34600493-5C42630E-BEE6-4B55-9950-A4471B6C51FCQ34757166-F3544A32-FE86-4758-88BD-E99E69070CDCQ34778531-2398373C-DFD8-4F91-8409-AA5BBE77A281Q34920590-3EBD3F3C-CB90-4E23-853F-9557053E85ACQ35026573-386C2740-D687-4450-9304-998BEB5BC14EQ35043048-F24DDBA1-BDCF-4D5C-9BA1-2C1F1F36884FQ35102656-15232F26-E80D-4B20-8E9F-90AA54C6C2FFQ35167188-AEBFE322-97F4-4F1B-B33D-12BB9B94E802Q35607808-6B527223-19BD-4BF8-ABCF-A06F0CA54C32Q35705874-442B4383-7303-4B67-9601-0D66C243C25CQ35719130-A5D3E6FE-DA14-4A54-ACED-5A5D3F4F28DDQ35738885-A0124330-D9A4-43B6-9699-49620B425818Q35776635-C2D95FBF-36E8-4E7D-9FA0-F22822E3C8DE
P2860
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@ast
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@en
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@nl
type
label
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@ast
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@en
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@nl
prefLabel
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@ast
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@en
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@nl
P2093
P2860
P1476
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.
@en
P2093
Gallicano K
Peloquin C
P2860
P304
P356
10.2165/00003088-200140050-00002
P577
2001-01-01T00:00:00Z
P5875
P6179
1000972929